Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX22 plus trastuzumab and chemotherapy versus placebo plus trastuzumab and chemotherapy in previously HER2-ADC-treated HER2-positive advanced breast cancer
CTR20263696Phase 2Active
- Sponsor
- HyBioPharma
- Start
- Oct 2026
- Modality
- Vaccines & Immunotherapeutics, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of hlx22 in breast cancer, sponsored by HyBioPharma. Started Oct 2026; status: active.
02
Drugs
hlx22
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20263696.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263696.